An enlarged prostate on ultrasound most commonly reflects benign prostatic enlargement (BPE), especially with increasing age. The scan may report prostate volume in mL/cc, median-lobe protrusion and post-void residual urine. Size alone does not tell how blocked the urinary passage is and does not diagnose prostate cancer. A relatively small prostate can cause severe obstruction, while a large prostate may cause few symptoms. Treatment decisions use urinary symptoms, flow rate, residual urine, complications, PSA and sometimes cystoscopy or urodynamics—not volume alone.

How prostate volume is calculated

Ultrasound usually measures length, width and height and applies an ellipsoid formula. Transabdominal measurements are approximate and depend on bladder filling and technique; transrectal ultrasound or MRI may provide different values. A prostate around or above 30 mL is often described as enlarged, but there is no single volume at which treatment becomes mandatory.

Why prostate size and symptoms do not match perfectly

Urinary symptoms come from a combination of static tissue bulk, smooth-muscle tone, bladder response and sometimes unrelated conditions such as diabetes or overactive bladder. This is why a 70 mL prostate may have a good flow while a 30 mL prostate with a tight bladder neck may produce significant obstruction.

Median lobe / intravesical protrusion

A prostate median lobe can protrude upward into the bladder and create a ball-valve type outlet effect. Intravesical prostatic protrusion may correlate with obstruction and can influence procedure choice, but it is still interpreted with flow, residual urine and symptoms.

Residual urine and bladder changes

Ultrasound may also show a high post-void residual, bladder wall thickening, trabeculation, diverticula or stones. These can suggest long-standing outlet problems. Hydronephrosis or impaired kidney function raises the urgency because it may indicate high-pressure retention or another cause of obstruction.

Does enlargement mean cancer?

No. BPH and prostate cancer are different processes and can coexist. Ultrasound size cannot exclude cancer. PSA, digital rectal examination, MRI and biopsy are used when cancer risk needs assessment.

When medicines may be considered

For bothersome LUTS, alpha-blockers can improve dynamic outlet resistance, while 5-alpha-reductase inhibitors are most useful in appropriately selected men with larger prostates and reduce prostate volume over time. Choice depends on symptoms, prostate size, blood pressure, sexual side effects and progression risk; treatment should be prescribed after evaluation.

When surgery/procedure is considered

• Recurrent urinary retention.
• Recurrent infection, bladder stones or bleeding attributable to BPH.
• Hydronephrosis/renal impairment from bladder outlet obstruction.
• Persistent bothersome symptoms despite appropriate medical treatment.
• Patient preference for definitive treatment after understanding options and trade-offs.

What prostate size can and cannot predict

Larger prostates are associated with a greater long-term risk of BPH progression and acute retention at a population level, but an individual patient may remain stable for years. Serial size measurements should not replace symptom review, flow and residual urine. A change of a few mL between ultrasound reports may simply reflect measurement technique rather than true biological growth.

How prostate volume changes treatment planning

Volume can influence which procedure is technically suitable. Very large glands may favour enucleation or simple prostatectomy approaches in appropriate patients, while smaller glands may be suited to other endoscopic or minimally invasive options. Median-lobe anatomy, anticoagulation, sexual priorities and local expertise also matter.

For medical therapy, prostate volume can help estimate progression risk and whether a 5-alpha-reductase inhibitor is likely to be useful. However, a man with mild symptoms and a large prostate does not automatically need surgery, and a man with severe complications should not be denied treatment because the gland is “only” moderately enlarged.

Why prostate size is a treatment-planning variable, not a diagnosis

Prostate volume becomes particularly useful when choosing therapy. It can influence whether a 5-alpha-reductase inhibitor is reasonable and which procedure is technically suited to the gland—incision, resection, enucleation, simple prostatectomy or selected minimally invasive options. Median-lobe/intravesical protrusion can matter as much as total volume for some procedures.

What prostate size does not tell you is whether the bladder is actually obstructed. Symptoms, uroflowmetry, residual urine, bladder changes and sometimes urodynamics answer different parts of that question.

What to bring for consultation

• Ultrasound report with prostate volume and PVR.
• Uroflowmetry curve.
• PSA values when appropriate.
• Urine routine/culture and creatinine.
• Current prostate medicines and prior catheter/retention history.

FAQs

Related reading

• PSA Report Explained
• Uroflowmetry Report Explained
• Post-Void Residual Urine Explained
• Bladder Wall Thickening on Ultrasound
• Trabeculated Bladder on Ultrasound
• Urologist in Latur

References

• European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male LUTS: Diagnostic Evaluation. 2026 https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/diagnostic-evaluation
• European Association of Urology. EAU Guidelines on Prostate Cancer: Diagnostic Evaluation. 2026 https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation